Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Buus R, Quang LH, Thi Han P, Khoa PH, Dinh NV, To TV, Clemons M, Holcombe C, Osborne C, Evans A, Skene A, Sibbering M, Rogers C, Laws S, Noor L, Smith IE, Dowsett M.

NPJ Breast Cancer. 2019 Nov 15;5:42. doi: 10.1038/s41523-019-0138-2. eCollection 2019.

2.

Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.

Leal MF, Haynes BP, Schuster E, Yeo B, Afentakis M, Zabaglo L, Martins V, Buus R, Dodson A, Cheang MCU, Smith IE, Martin LA, Dowsett M.

Clin Cancer Res. 2019 Dec 15;25(24):7485-7496. doi: 10.1158/1078-0432.CCR-19-1129. Epub 2019 Sep 23.

PMID:
31548345
3.

Retained Acetylated Histone Four in Bull Sperm Associated With Fertility.

Ugur MR, Kutchy NA, de Menezes EB, Ul-Husna A, Haynes BP, Uzun A, Kaya A, Topper E, Moura A, Memili E.

Front Vet Sci. 2019 Jul 31;6:223. doi: 10.3389/fvets.2019.00223. eCollection 2019.

4.

Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach.

Leal MF, Haynes BP, MacNeill FA, Dodson A, Dowsett M.

Breast Cancer Res Treat. 2019 Jun;175(2):317-326. doi: 10.1007/s10549-019-05163-6. Epub 2019 Feb 22.

5.

Adrenergic receptor blockade attenuates placental ischemia-induced hypertension.

Spradley FT, Ge Y, Haynes BP, Granger JP, Anderson CD.

Physiol Rep. 2018 Sep;6(17):e13814. doi: 10.14814/phy2.13814.

6.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

7.

Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2015 Jan;149(1):311. doi: 10.1007/s10549-014-3210-5. No abstract available.

PMID:
25425349
8.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M.

Clin Cancer Res. 2015 Jul 1;21(13):2932-40. doi: 10.1158/1078-0432.CCR-14-1428. Epub 2014 Nov 14.

9.

Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2014 Nov;148(2):327-35. doi: 10.1007/s10549-014-3181-6. Epub 2014 Nov 4. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(1):311.

PMID:
25367875
10.

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.

Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, Folkerd EJ, Haynes BP, Hopper JL, Southey MC, Dite GS, Apicella C, Schmidt MK, Broeks A, Van't Veer LJ, Atsma F, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Ekici AB, Renner SP, Sawyer E, Tomlinson I, Kerin M, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina E, Menegaux F, Bojesen SE, Nordestgaard BG, Flyger H, Milne R, Zamora MP, Arias Perez JI, Benitez J, Bernstein L, Anton-Culver H, Ziogas A, Clarke Dur C, Brenner H, Müller H, Arndt V, Dieffenbach AK, Meindl A, Heil J, Bartram CR, Schmutzler RK, Brauch H, Justenhoven C, Ko YD; GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Matsuo K, Dörk T, Bogdanova NV, Antonenkova NN, Lindblom A, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G, Beesley J; kConFab Investigators; Australian Ovarian Cancer Study Group, Wu AH, Van den Berg D, Tseng CC, Lambrechts D, Smeets D, Neven P, Wildiers H, Chang-Claude J, Rudolph A, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Pensotti V, Couch FJ, Olson JE, Wang X, Fredericksen Z, Pankratz VS, Giles GG, Severi G, Baglietto L, Haiman C, Simard J, Goldberg MS, Labrèche F, Dumont M, Soucy P, Teo S, Yip CH, Phuah SY, Cornes BK, Kristensen VN, Grenaker Alnæs G, Børresen-Dale AL, Zheng W, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devillee P, Figueroa J, Chanock SJ, Lissowska J, Sherman ME, Hall P, Schoof N, Hooning M, Hollestelle A, Oldenburg RA, Tilanus-Linthorst M, Liu J, Cox A, Brock IW, Reed MW, Cross SS, Blot W, Signorello LB, Pharoah PD, Dunning AM, Shah M, Kang D, Noh DY, Park SK, Choi JY, Hartman M, Miao H, Lim WY, Tang A, Hamann U, Försti A, Rüdiger T, Ulmer HU, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Vachon C, Yannoukakos D, Shen CY, Yu JC, Huang CS, Hou MF, González-Neira A, Tessier DC, Vincent D, Bacot F, Luccarini C, Dennis J, Michailidou K, Bolla MK, Wang J, Easton DF, García-Closas M, Dowsett M, Ashworth A, Swerdlow AJ, Peto J, dos Santos Silva I, Fletcher O.

Breast Cancer Res. 2014 May 26;16(3):R51. doi: 10.1186/bcr3662.

11.

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.

Lønning PE, Haynes BP, Dowsett M.

Eur J Cancer. 2014 Apr;50(6):1055-64. doi: 10.1016/j.ejca.2014.01.007. Epub 2014 Feb 4.

12.

Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.

Flågeng MH, Knappskog S, Haynes BP, Lønning PE, Mellgren G.

PLoS One. 2013 Aug 22;8(8):e74618. doi: 10.1371/journal.pone.0074618. eCollection 2013.

13.

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A'Hern R, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2013 Feb;138(1):157-65. doi: 10.1007/s10549-013-2426-0. Epub 2013 Feb 3.

PMID:
23378065
14.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

15.

Exploring breast cancer estrogen disposition: the basis for endocrine manipulation.

Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, Dowsett M.

Clin Cancer Res. 2011 Aug 1;17(15):4948-58. doi: 10.1158/1078-0432.CCR-11-0043. Epub 2011 Jul 26. Review.

16.

Recent data on intratumor estrogens in breast cancer.

Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, Dowsett M.

Steroids. 2011 Jul;76(8):786-91. doi: 10.1016/j.steroids.2011.02.040. Epub 2011 Mar 31. Review.

PMID:
21439992
17.

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

Anderson H, Hills M, Zabaglo L, A'hern R, Leary AF, Haynes BP, Smith IE, Dowsett M.

Ann Oncol. 2011 Aug;22(8):1770-6. doi: 10.1093/annonc/mdq700. Epub 2011 Feb 1.

18.

Intratumoral estrogen disposition in breast cancer.

Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, Lønning PE, Dowsett M.

Clin Cancer Res. 2010 Mar 15;16(6):1790-801. doi: 10.1158/1078-0432.CCR-09-2481. Epub 2010 Mar 9.

19.

Pruning artificial neural networks using neural complexity measures.

Jorgensen TD, Haynes BP, Norlund CC.

Int J Neural Syst. 2008 Oct;18(5):389-403.

PMID:
18991362
20.

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

Johnston SR, Gumbrell LA, Evans TR, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A, Canney P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarman M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC; Cancer Research UK Phase I/II Committee.

Cancer Chemother Pharmacol. 2004 Apr;53(4):341-8. Epub 2004 Jan 13.

PMID:
14722733
21.

The pharmacology of letrozole.

Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS.

J Steroid Biochem Mol Biol. 2003 Oct;87(1):35-45. Review.

PMID:
14630089
22.

Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen.

Dowsett M, Haynes BP.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):255-63. Review.

PMID:
14623519
23.

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.

Cancer Res. 1999 Aug 1;59(15):3646-51.

24.

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors.

Barrie SE, Haynes BP, Potter GA, Chan FC, Goddard PM, Dowsett M, Jarman M.

J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):347-51.

PMID:
9219927
25.
26.
27.

Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy.

Young H, Carnochan P, Trivedi M, Potter GA, Eccles SA, Haynes BP, Jarman M, Ott RJ.

Nucl Med Biol. 1995 May;22(4):405-11.

PMID:
7550016
28.

Idoxifene: report of a phase I study in patients with metastatic breast cancer.

Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R, Jarman M.

Cancer Res. 1995 Mar 1;55(5):1070-4.

29.

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M.

J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73.

PMID:
7918112
30.

Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

Johnston SR, Haynes BP, Smith IE, Jarman M, Sacks NP, Ebbs SR, Dowsett M.

Lancet. 1993 Dec 18-25;342(8886-8887):1521-2.

PMID:
7902904
31.

Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.

Johnston SR, Haynes BP, Sacks NP, McKinna JA, Griggs LJ, Jarman M, Baum M, Smith IE, Dowsett M.

Breast Cancer Res Treat. 1993 Dec;28(3):241-50.

PMID:
8018953
32.

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Haynes BP, Jarman M, Dowsett M, Mehta A, Lønning PE, Griggs LJ, Jones A, Powles T, Stein R, Coombes RC.

Cancer Chemother Pharmacol. 1991;27(5):367-72.

PMID:
1847846
34.

The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S, Breckenridge AM, Preston FE, Park BK.

Br J Clin Pharmacol. 1988 Jan;25(1):1-7.

35.

Hepatic enzyme induction and vitamin K1 elimination in man.

Scott AK, Haynes BP, Schinkel KD, Ohnhaus EE, Park BK.

Eur J Clin Pharmacol. 1987;33(1):93-5.

PMID:
3691603
36.

Enantiomers of warfarin and vitamin K1 metabolism.

Choonara IA, Haynes BP, Cholerton S, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1986 Dec;22(6):729-32.

37.

Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins.

Park BK, Choonara IA, Haynes BP, Breckenridge AM, Malia RG, Preston FE.

Br J Clin Pharmacol. 1986 Mar;21(3):289-93.

38.

Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1986 Mar;21(3):271-7.

39.

Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients.

Choonara IA, Scott AK, Haynes BP, Cholerton S, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1985 Dec;20(6):643-8.

40.

Plasma disposition of vitamin K1 in relation to anticoagulant poisoning.

Park BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM.

Br J Clin Pharmacol. 1984 Nov;18(5):655-62.

41.

A study of factors which determine the pharmacological response to vitamin K in coumarin anticoagulated rabbits.

Hart JA, Haynes BP, Park BK.

Biochem Pharmacol. 1984 Oct 1;33(19):3013-9.

PMID:
6487353
42.

Supplemental Content

Loading ...
Support Center